Abstract 345P
Background
Breast cancer surgery can impair shoulder function, and the effects of rehabilitation exercise during early recovery remain uncertain. This study aims to assess the effectiveness of tailored exercise intervention on shoulder function recovery at one and six months post-surgery.
Methods
A total of 122 breast cancer patients (Stage 0-3) scheduled for surgery were evaluated, and 58 patients (mean age 50.2±6.6 years) were randomly assigned to an exercise or usual care group (1:1). The exercise group underwent five tailored exercise education sessions, starting one day before hospital discharge and continuing for four weeks after surgery. Participants received exercise diaries, online links, and QR codes for home-based workouts. The primary outcome measured the proportion of participants achieving 90% of their pre-surgery shoulder ROM and strength at one and six months post-surgery. Secondary measures included DASH and SPADI scores, physical activity levels, and body composition.
Results
Out of 58 participants, 56 (96.6%) completed the trial, with a 96.6% exercise compliance rate one month after surgery. In the exercise group, 92.9% and 96.2% achieved pre-surgery shoulder strength levels at one and six months post-surgery, respectively, compared to 3.7% and 32.1% in the control group. The exercise group also exhibited significantly lower shoulder pain and disability scores (SPADI) at one and six months after surgery, as well as higher physical activity levels at six months. Table: 345P
Change in shoulder strength among postoperative breast cancer patients
Affected arm | |||
EPET (n=25) | Usual Care (n=26) | p | |
Sum of strength (Ib) | |||
T0 | 44.1±10.2 | 47.5±11.1 | 0.36 |
T1 | 23.2±10.3∗∗∗ | 23.8±9.4∗∗∗ | 0.80 |
T2 | 40.4±11.9 | 28.5±11.9∗∗∗ | 0.001 |
T3 | 45.9±14.7 | 32.0±11.2∗∗∗ | <0.001 |
T4 | 51.3±14.0 | 32.0±9.2∗∗∗ | <0.001 |
T5 | 61.0±17.1∗∗∗ | 38.3±8.4∗∗∗ | <0.001 |
Mean±SD, P=represented the results of independent T-test (the p-value adjusted for Bonferroni method (0.05/6=0.0083), *=represented paired t-test [**p<0.01 vs. baseline, ***p<0.001 vs. baseline (p-value adjusted for Bonferroni method)] Abbreviation: early postoperative exercise therapy; EPET
.Conclusions
Early implementation of tailored exercise during rehabilitation significantly improved shoulder function beyond pre-surgery levels. This study provides essential insights into the efficacy and safety of early rehabilitation exercises for breast cancer patients during the post-surgery recovery phase.
Clinical trial identification
The Institutional Ethics Review Board of Severance Hospital and WHO International Clinical Trials Registry Platform (ICTRP; KCT0006997) approved the trial.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This research was supported by the Ministry of Education of the Republic of Korea, the National Research Foundation of Korea (NRF-2020S1A5B5A17090332) and Korea Breast Cancer Foundation (KBCF-2020U002).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
393P - Real-world (RW) use patterns, effectiveness, and tolerability of sacituzumab govitecan (SG) for second-line (2L) and later treatment of metastatic triple-negative breast cancer (mTNBC)
Presenter: Kevin Kalinsky
Session: Poster session 03
394P - CDK4/6 inhibitors in metastatic breast cancer: An Italian real-world experience
Presenter: Francesco Pantano
Session: Poster session 03
395P - Interim analysis (IA) of the giredestrant (G) + ipatasertib (IPAT) arm in MORPHEUS Breast Cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with oestrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC)
Presenter: Kyung Jung
Session: Poster session 03
396P - Real-world treatment and survival outcomes in previously untreated patients with metastatic triple-negative breast cancer (mTNBC) in the United States (US)
Presenter: Kevin Punie
Session: Poster session 03
398P - A phase Ib/II study of IN10018/FAKi in combination with pegylated liposomal doxorubicin (PLD) and toripalimab in metastatic triple-negative breast cancer (TNBC): IN10018-010
Presenter: Xichun Hu
Session: Poster session 03
399P - Results from a first-in-human phase Ia/b study of LX-039, an oral selective estrogen receptor (ER) degrader (SERD), in postmenopausal patients with ER+, HER2- advanced breast cancer (ABC)
Presenter: weina shen
Session: Poster session 03
400P - The impact of CDK4/6 inhibitors on bone health: An Italian real-world experience
Presenter: Roberta Scafetta
Session: Poster session 03
401P - Utidelone in combination with etoposide and bevacizumab in HER2-negative breast cancer with brain metastasis (UTOBIA-BM): A prospective, single-arm, phase II trial
Presenter: Yehui Shi
Session: Poster session 03
402P - First-line ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in aggressive HR+/HER2− advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without visceral crisis from the phase II RIGHT choice study
Presenter: Hamdy Azim
Session: Poster session 03